Growth Companies With High Insider Ownership On SEHK October 2024

As global markets experience varied economic shifts, Hong Kong's Hang Seng Index has recently faced a downturn amid waning optimism about Beijing's stimulus measures. In this fluctuating environment, growth companies with high insider ownership on the SEHK can offer unique insights into potential resilience and alignment of interests between management and shareholders.

Top 10 Growth Companies With High Insider Ownership In Hong Kong

Name	Insider Ownership	Earnings Growth
Laopu Gold (SEHK:6181)	36.4%	33.2%
Akeso (SEHK:9926)	20.5%	53%
Fenbi (SEHK:2469)	33.1%	22.4%
Zylox-Tonbridge Medical Technology (SEHK:2190)	18.8%	69.8%
Pacific Textiles Holdings (SEHK:1382)	11.2%	37.7%
Ocumension Therapeutics (SEHK:1477)	24%	95.6%
DPC Dash (SEHK:1405)	38.1%	104.8%
Beijing Airdoc Technology (SEHK:2251)	29.4%	93.4%
Zhejiang Leapmotor Technology (SEHK:9863)	15%	71.8%
Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)	13.9%	109.2%

Click here to see the full list of 48 stocks from our Fast Growing SEHK Companies With High Insider Ownership screener.

Underneath we present a selection of stocks filtered out by our screen.

Ocumension Therapeutics (SEHK:1477)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Ocumension Therapeutics, along with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China with a market cap of HK$4.03 billion.

Operations: The company's revenue segment focuses on discovering, developing, and commercializing ophthalmic therapies, generating CN¥310.29 million.

Insider Ownership: 24%

Earnings Growth Forecast: 95.6% p.a.

Ocumension Therapeutics, with substantial insider ownership, is poised for significant growth. The company expects to become profitable within three years and forecasts a 39.3% annual revenue increase, outpacing the Hong Kong market. Recent developments include the approval of OT-1001 by China's NMPA and a special shareholders meeting to approve key transactions. Despite past losses, Ocumension's strategic share buyback program aims to enhance shareholder value and improve financial metrics such as earnings per share.

• Click to explore a detailed breakdown of our findings in Ocumension Therapeutics' earnings growth report.
• The valuation report we've compiled suggests that Ocumension Therapeutics' current price could be quite moderate.

Vobile Group (SEHK:3738)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Vobile Group Limited is an investment holding company offering software as a service for digital content asset protection and transactions in the United States, Japan, Mainland China, and internationally, with a market cap of HK$5.70 billion.

Operations: The company's revenue is primarily derived from its software as a service (SaaS) offerings, totaling HK$2.18 billion.

Insider Ownership: 23.1%

Earnings Growth Forecast: 68.5% p.a.

Vobile Group shows strong growth prospects with earnings forecasted to rise 68.5% annually, surpassing the Hong Kong market's average. Despite recent share price volatility and past shareholder dilution, the company is trading slightly below its estimated fair value. The commencement of a share buyback program aims to enhance net asset value and earnings per share. Recent financials reveal increased sales and net income for H1 2024, indicating positive momentum despite narrower profit margins compared to last year.

• Navigate through the intricacies of Vobile Group with our comprehensive analyst estimates report here.
• The valuation report we've compiled suggests that Vobile Group's current price could be inflated.

Akeso (SEHK:9926)

Simply Wall St Growth Rating: ★★★★★★

Overview: Akeso, Inc. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of antibody drugs, with a market cap of HK$58.83 billion.

Operations: The company generates revenue of CN¥1.87 billion from its activities in researching, developing, producing, and selling biopharmaceutical products.

Insider Ownership: 20.5%

Earnings Growth Forecast: 53% p.a.

Akeso demonstrates strong growth potential with revenue expected to grow 33.5% annually, significantly outpacing the Hong Kong market. The company is forecasted to achieve profitability within three years and currently trades at a substantial discount to its estimated fair value. Recent positive clinical trial results for cadonilimab highlight its commercialization potential in oncology, while new drug approvals like ebronucimab expand Akeso's portfolio into non-oncology areas, supporting diversified growth strategies.

• Unlock comprehensive insights into our analysis of Akeso stock in this growth report.
• Our valuation report unveils the possibility Akeso's shares may be trading at a premium.

Seize The Opportunity

• Click through to start exploring the rest of the 45 Fast Growing SEHK Companies With High Insider Ownership now.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com